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Abstract
Background: Infertility is a known side-effect of oncotherapy in cancer survivors, and often compromises the
quality of life. The present study was undertaken to detect very small embryonic-like stem cells (VSELs) in testicular
biopsies from young adult survivors of childhood cancer who had azoospermia. VSELs have been earlier reported in
human and mouse testes. They resist busulphan treatment in mice and potentially restore spermatogenesis when
the somatic niche is restored by transplanting Sertoli or mesenchymal cells. VSELs also have the potential to
differentiate into sperm in vitro.
Methods: The study had clearance from Institutional review board (IRB). Seven azoospermic survivors of childhood
cancer were included in the study after obtaining their informed consent. Semen analysis was done to confirm
azoospermia prior to inclusion in the study. Testicular biopsies were performed at the Uro-oncology Unit of the
hospital and then used for various studies to detect VSELs.
Results: Hematoxylin and Eosin stained tubular sections confirmed azoospermia and smears revealed the presence
of very small, spherical VSELs with high nucleo-cytoplasmic ratio, in addition to the Sertoli cells. Immuno-localization
studies on testicular smears showed that the VSELs were CD133+/CD45-/LIN-, expressed nuclear OCT-4, STELLA and
cell surface SSEA-4. Pluripotent transcripts Oct-4A, Nanog and Sox-2 were detected in azoospermic samples whereas
marked reduction was observed in germ cell markers Oct-4 and Boule.
Conclusions: The present study demonstrates the presence of pluripotent VSELs in the testicular biopsy of
azoospermic adult survivors of childhood cancer. It is likely that these persisting VSELs can restore spermatogenesis
as demonstrated in mice studies. Therefore, pilot studies need to be undertaken using autologous mesenchymal cells
with a hope to restore testicular function and fertility in cancer survivors. The results of this study assume a great
significance in the current era, where cryopreservation of testicular tissue in young pre-pubertal boys for restoring
spermatogenesis in adulthood is still in experimental stages.
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Background
With recent advances in the field of oncotherapy, more
than 80 % pediatric patients survive cancer [1]. This has
resulted in an increasing focus on the late effects of therapy
and quality of life in the growing population of childhood
cancer survivors. Approximately 2 of every 3 childhood
cancer survivors will experience at least one late effect, and
40 % may develop a ‘severe, disabling, or life-threatening
condition’ 30 years after cancer diagnosis [2].
Late effects on the reproductive system can be mani-
fold. Chemotherapy, surgery and radiotherapy can affect
either the hypothalamo-pituitary axis or the gonads
themselves, and can lead to infertility and other side
effects on the reproductive system. Several studies have
found that infertility is a common late effect of treat-
ment in adult male survivors of childhood cancer [3–7].
A large study found that cancer survivors have a lower
chance of siring a pregnancy than their siblings (hazard
ratio 0.56) [3]. The treatment factors commonly impli-
cated in male gonadal dysfunction include cumulative
alkylating agent (cyclophosphamide and procarbazine)
dose, radiation to testes, pelvis/abdomen and hypothal-
amus/pituitary and orchidectomy [3, 4, 8–10].
Presently, sperm banking is the only widely established
and successful fertility preservation method for males,
but is technically challenging and even not possible at
times in children and teenagers. Importantly, the diagno-
sis of a malignancy is devastating to the child’s family
and treatment is usually initiated urgently. Discussions
regarding late effects including infertility tend to take a
backseat, especially in resource poor settings. The only
available options today in pre pubertal boys is testicular
tissue cryopreservation as tubules or germ cells and later
transplantation or testis xenografting to obtain mature
sperm for assisted reproduction. These are yet experi-
mental approaches [11, 12]. Due to the above reasons,
fertility preservation is often a low priority in Paediatric
Oncology centers. In many instances, adult survivors of
childhood cancer become aware of this late effect only
when confronted with infertility and at this stage treat-
ment options are limited and extremely disappointing.
They undergo severe psychosocial trauma and often
wish that they had more information and options re-
garding their fertility, and that they had undergone fertil-
ity preservation prior to cancer treatment.
Besides sperm banking and testicular biopsy for future
use, research on pluripotent stem cells has provided a ray
of hope as these stem cells have potential to differentiate
into ‘synthetic’ gametes. Several groups across the world
have reported differentiation of pluripotent embryonic stem
(ES) cells and induced pluripotent stem (iPS) cells into
germ cells. However, these approaches remain highly ineffi-
cient and are still a distant dream [13]. Besides ES and iPS
cells, an additional novel population of pluripotent stem
cells termed very small embryonic-like stem cells (VSELs)
reported in various adult organs including testis and ovary
[14–18] may serve as an alternative candidate to obtain
gametes for achieving biological parenthood [19]. These
stem cells are relatively quiescent in nature and thus have
been reported to survive total body irradiation in mouse
bone marrow [20] and after busulphan and cyclophospha-
mide treatment in mouse testis [21] and ovary [22]. VSELs
are located in the basal layer of seminiferous epithelium in
the testis and in the ovary surface epithelium. They are
pluripotent cells believed to be the primordial germ cells
which persist throughout life albeit in few numbers [23]
and get mobilized under disease conditions to regenerate
and bring about homeostasis [24]. VSELs indeed serve as a
backup pool of stem cells which occasionally self-renew
themselves and also give rise to the progenitors by under-
going asymmetric cell divisions. The progenitors including
spermatogonial stem cells (SSCs) in testis and ovary germ
stem cells (OGSCs) in ovary divide by undergoing rapid
symmetric cell divisions followed by further differentiation
and meiosis to form the gametes. Existence of similar two
populations including ‘dormant’ and ‘restless’ stem cells has
been also reported in gut epithelium, hair follicle, bone
marrow and skin [25–27].
Anand et al. [21] demonstrated that the testicular
VSELs which survive busulphan treatment in mice are
capable of restoring spermatogenesis and the caudal
sperm fertilized oocytes in vitro resulting in early embry-
onic development. This was achieved by providing a
healthy somatic niche to the surviving VSELs by way of
inter-tubular transplanting Sertoli or mesenchymal cells.
The transplanted cells provided a source of growth
factors and cytokines required for VSELs to undergo
spermatogenesis. Similarly the surviving VSELs in che-
moablated mice ovaries also initiated differentiation into
oocytes [22]. Anand et al. [28] have also recently studied
the potential of VSELs surviving in chemoablated testis
to undergo spermatogenesis in vitro. Since VSELs have
been reported in adult human testicular tissue earlier
[14] the present study was undertaken to investigate
whether the VSELs survive in otherwise azoospermic
testicular biopsies of adult survivors of childhood cancer.
Presence of VSELs in azoospermic testicular biopsies
open up an altogether novel approach to restore fertility
with an aim to achieve biological parenthood and thus
indirectly help improve quality life of cancer survivors.
Methods
Approval was obtained from the IRB of Tata Memorial
Hospital, Mumbai to collect testicular biopsy from male
survivors of childhood cancer and one normal testicular
sample was obtained from a patient undergoing orchidec-
tomy as part of treatment for prostate cancer as normal
control.
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Testicular biopsy collection
Seven adult survivors of various types of childhood can-
cers were evaluated for infertility in After Completion of
Therapy (ACT) clinic for long term survivors of child-
hood cancers using semen analysis, circulating follicular
stimulating hormone (FSH) and testosterone levels prior
to being enrolled for the study. Once azoospermic status
was confirmed, the participants were subjected to a tes-
ticular biopsy under sterile conditions. In brief, 10–12
pieces of testicular biopsy, each measuring 1–2 mm3
were collected sites from a single testis under local
anesthesia. The procedure lasted about 10–15 min. Nor-
mal testicular tissue was also collected from a patient
undergoing orchidectomy as part of treatment towards
prostate cancer after appropriate informed consent. The
specimens were collected in sterile DMEM F12 medium
(Invitrogen, USA) with antibiotics on ice and were proc-
essed appropriately for histology, smear preparation and
for RNA extraction.
Tissue processing
A part of human testicular biopsy was fixed in 10 % neu-
tral buffer formalin for histological studies. 5 μm thick
sections of paraffin embedded tubules were prepared and
stained with Hematoxylin and eosin (H & E) to study the
tissue histo-architecture. Testicular cell smears were pre-
pared by fine chopping of tissue and filtration through a
40 μm filter. The smears were then fixed with 4 % parafor-
maldehyde and stored at 4 °C till further use. A portion of
tissue was fixed in Trizol (Invitrogen) for RNA isolation
and stored at -80 °C till further processing.
Immuno localization studies
The cell smears were used to immuno-localize pluripotent
markers (OCT-4; SSEA-4), primordial germ cell marker
(STELLA) and for VSELs specific marker (CD133). The
cells were permeabilized using 0.3 % Triton-X 100 for
5 min following washes with 0.5 % bovine serum albumin
(BSA). The permeabilization step was omitted for cell sur-
face markers. Blocking was done with 3 % BSA solution
for 1 h. Smears were incubated overnight with primary
antibodies namely OCT-4 (Abcam, UK), SSEA-4 (Milli-
pore, USA), STELLA (Millipore), CD133 (Miltenyi, USA)
at 4 °C. For co-localization study, directly tagged CD133-
APC (Miltenyi, USA), LIN - FITC (BD) and CD45-PE
(BD) were used. After washing with 0.5 % BSA, the smears
were blocked with 1 % BSA and 5 % normal goat serum
for 1 h followed by incubation with antibodies for 2 h at
room temperature. The cells were then washed thrice with
wash buffer and counterstained with DAPI (4',6-diami-
dino-2-phenylindole dihydrochloride) for 15 min. All im-
ages were captured by laser scanning confocal microscope
(Carl Zeiss, Germany) at 63 X magnification.
Quantitative RT-PCR
Extracted RNA was treated with DNase I (Amersham
Biosciences, USA) to remove any genomic DNA con-
tamination. First-strand cDNA was synthesized using
the iScript cDNA synthesis Kit (Bio-Rad, USA) accord-
ing to the manufacturer’s instructions. 1 μg of total RNA
was incubated with 5x iScript reaction mix and reverse
transcriptase mix. The reaction was carried out in G-
STORM thermocycler (Gene Technologies, UK). The re-
action mix was first incubated at 25 °C for 5 min, then
at 42 °C for 30 min and finally at 85 °C for 5 min. The
expression levels of various gene transcripts, namely
total Oct-4A, Oct-4B, Nanog, Sox-2, Boule, and TP1
gene transcripts were studied using 18 s as housekeeping
gene, and were estimated by CFX96 real-time PCR
system (Bio-Rad Laboratories, USA) using SYBR Green
chemistry (Bio-Rad). The primers used in the study are
mentioned in Table 1. The amplification conditions
were: initial denaturation at 94 °C for 3 min followed by
40 cycles comprising of denaturation at 94 °C for 10 s,
primer annealing for 20 s, and extension at 72 °C for
30 s followed by melt curve analysis step from 55 °C to
95 °C. The fluorescence emitted at each cycle was col-
lected during the extension step of each cycle. The
homogeneity of the PCR amplicons was verified by run-
ning the products on 2 % agarose gels and also by study-
ing the melt curve. All PCR amplifications were carried
out in duplicate. Mean Ct values generated in each ex-
periment using the CFX Manager software (Bio-Rad)
were used to calculate the mRNA expression levels.
Since ΔCt is inversely proportional to relative mRNA
expression levels, the levels were calculated manually by
the ΔCt method.
Results
The clinical and previous treatment details of the seven
adult survivors of childhood cancer included in the
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study are as described in Table 2. Initial screening by
semen analysis and hormone assays confirmed that all
participants were azoospermic and had normal to raised
FSH and testosterone levels. All seven survivors agreed
to participate in the study with a strong desire to attain
biological parenthood, although they were informed
about the basic nature of the present study.
The H&E stained testicular sections confirmed the pres-
ence of azoospermia as evidenced by the presence of
empty tubules with no signs of germ cells and sperm
(Fig. 1). The testicular cell smears comprised of Sertoli
cells and VSELs. VSELs were identified as small sized,
spherical in shape and had a typical dark Hematoxylin
stained nucleus and high nucleo-cytoplasmic ratio (Fig. 1).
Sertoli cells had abundant cytoplasm and characteristic
pale stained nuclei and prominent nucleolus (Fig. 1).
Immuno-fluorescence studies were done to characterize
VSELs for the expression of pluripotency and VSEL spe-
cific markers namely OCT-4 and SSEA-4 (Fig. 2). Also,
co-localization studies showed CD133 positive cells were
negative for LIN and CD45 markers (Fig. 2). The presence
of pluripotent VSELs in the azoospermic testicular biopsy
was further confirmed by the differential expression of
pluripotent (Oct-4A, Nanog, Sox2) and germ cell (Boule)
specific transcripts by qRT-PCR. The azoospermic sam-
ples revealed unaltered or slightly increased expression of
pluripotent markers (Oct-4A, Nanog and Sox2) (Fig. 3)
whereas the germ cell marker Boule was down regulated
compared to normal testicular sample. Although Oct-4A
levels remained similar to normal testicular sample, Oct-
4B was reduced indicating decrease in actively dividing
progenitors. Thus, similar to the effect of busulphan
treatment in mice [21], VSELs survived post-oncotherapy
in humans whereas germ cells and sperm were completely
lacking in the azoospermic testicular biopsies.
Discussion
With improving childhood cancer treatment protocols in
past few decades more child hood cancer survivors have
been detected with late side effects of such oncotherapy.
The two important aspects of this issue are (i) to risk-
adapt and optimize treatment protocols in order to reduce
the incidence of side effects while maximizing cure and
(ii) monitoring and management of late effects of child-
hood cancer survivors. The bulk of current translational
and clinical research in pediatric oncology focuses on the
first aspect and children treated on current protocols are
anticipated to have fewer and less severe late effects of
treatment [29, 30]. The second aspect of managing survi-
vors at high risk of late effects or those already facing late
effects is more challenging.
At Tata Memorial Hospital Mumbai, the After Comple-
tion of Therapy (ACT) Clinic was set up in 1991 for the
comprehensive follow- up of childhood cancer survivors.
This clinic drew its inspiration from the model of care
established at St. Jude Children Research Hospital, USA,
and attempts to achieve “cure” in its true perspective [31].
At present there are 1700 survivors (disease free for more
than 2 years after cessation of therapy) who are registered
in the ACT Clinic. Infertility was recognized as a serious
late effect in our cohort of male cancer survivors [32].
Premarital fertility counseling is routinely offered to all
young adult survivors, which includes discussion about
their fertility issues, semen analysis, available options like
Table 2 Details of the Human Participants Included in the Study











1 35 years 12 years Hodgkin’s Lymphoma; CT + RTCT : Cyclophosphamide-9.6gm/m2RT
to bilateral neck 40Gy/20#
Azoospermia - -
2 35 years 12.6 years Lymphoblastic lymphoma;CT+ RTCT : Cyclophosphamide 22.4gm/
m2RT : Cranial 18Gy/9#Mediastinum 40 Gy/20#
Azoospermia - -
3 30 year 5 years at first
diagnosis27 years at
recurrence
Non Hodgkin’s lymphoma with recurrence/ transformation to
Diffuse Large B cell LymphomaSurgery + CT+ RTSurgery-Right
OrchiectomyCT: Cyclophosphamide 16gm/m2RT: Cranial 18Gy/9#CT
aloneCyclophosphamide-5.5 gm/m2
Azoospermia WNL WNL
4 35 years 8 years Wilms tumor : Surgery + CT+ RTSurgery-Left nephrectomyCT:
Cyclophosphamide-10.8 gm/m2,RT to left renal fossa 20 Gy/7#
Azoospermia Elevated WNL
5 28 years 7 years Hodgkin Lymphoma; CT + RTCT : Cyclophosphamide- 9.3 gm/m2;
Procarbazine-10 gm/m2RT to bilateral neck 36 Gy/18#
Azoospermia Elevated WNL
6 23 years 13 years Non Hodgkin lymphoma;CT + RTCT :Cyclophosphamide 20 g/m2RT:
Cranial 19.8Gy/11#
Azoospermia Elevated Elevated
7 25 years 10 year Non Hodgkin lymphoma; CT + RTCT : Cyclophosphamide 19gm/
m2RT: Cranial 19.8Gy/11#
Azoospermia Elevated Elevated
CT – chemotherapy; RT- Radiotherapy; Gy –gray; WNL- Within normal range
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donor sperm or adoption and most importantly sharing
the disease status with prospective spouse.. Since we do
not have in-house facilities for Assisted Reproduction
Technologies (ART), we refer our infertile survivors to
appropriate specialists at other Centres.
ACT Clinic database for reproductive outcome in mar-
ried young adult survivors revealed that 604 young adult
survivors (> 18 years of age) were registered of whom 188
were females and 416 were males. Among the female can-
cer survivors, 89 are lost to follow-up, 21 are married, 1 is
divorced and 11 of the unmarried female cancer survivors
are on hormone replacement therapy. Fertility outcome
available in 13 married females shows that 10 have normal
offspring and 3 are currently pregnant. So far, none of the
married females have approached us with the concern of
infertility. Amongst the 416 male survivors, 180 are lost to
follow up. Of the 70 married male survivors, only 30 were
able to sire a pregnancy naturally; the rest were found to
have either azoospermia or oligospermia when evaluated
for complaints of infertility or during premarital counsel-
ing. 17 of these infertile survivors underwent assisted re-
productive techniques (successful in 6 instances), 3 have
Fig. 1 VSELs in testicular biopsy of azoospermic men survivors of childhood cancer. a Testicular smear showing the presence of two types of
cells including Sertoli cells (with abundant cytoplasm, pale stained nuclei and prominent nucleolus) and spherical, small sized VSELs with dark
stained nuclei (arrows). Please note that several fields have been combined to make this composite. (b) H & E stained testicular section showing
empty tubules completely devoid of germ cells and sperm (c) Various representative fields showing Sertoli cells and VSELs at higher
magnification. Scale: 20 μm
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adopted and the remaining 20 currently do not have chil-
dren. All the offspring born to both male and female can-
cer survivors have been reported to be healthy. Of the 40
azoospermic/ oligospermic survivors, the most common
diagnosis was Hodgkin Lymphoma (HL; n = 27) followed
by Acute Lymphoblastic Leukemia (ALL; n = 4), Non
Hodgkin Lymphoma (NHL; n = 3) and others (n = 3) . The
median current age of this cohort is 31 years (range 20–53
years), with the median age at diagnosis being 8.5 years
(range 3–16 years), and the time since cessation of treat-
ment being 19.5 years (range 5–38 years). 28/40 had
received alkylating agents (high dose cyclophosphamide
and /or procarbazine), 4 ALL survivors had received cra-
nial radiation and 3 had received abdomino-pelvic radi-
ation. The numbers were too small to derive statistical
significance. Seven of these patients were enrolled in this
study .The individual clinical details are in Table 2. All had
received alkylating agents and/or radiation. The median
time between treatment completion and enrolment into
the trial was 23 years (median 21–27 years).
We counseled 15 of these cancer survivors and 7
agreed to give a testicular biopsy for the present study.
They were highly motivated to participate in the study
with a hope that the results may benefit them in near
future. This study reveals the presence of VSELs in tes-
ticular biopsies collected from otherwise azoospermic
adult survivors of childhood cancer. The pluripotent
VSELs exhibited characteristic spherical shape, high
high nucleo-cytoplasmic ratio, dark stained nuclei and
expressed nuclear OCT-4, cell surface SSEA-4 and
STELLA. As expected the testicular VSELs were LIN-/
CD45-/CD133+. Also the presence of VSELs was con-
firmed at mRNA level by the expression of pluripotent
transcripts Oct-4A, Nanog and Sox2. Absence of germ
cells was confirmed by histological studies and lack of
amplification of germ cell marker Boule. Due to scarcity
of clinical material extensive flow cytometry studies
could not be undertaken. Presence of these stem cells
in the azoospermic human testicular biopsies raises a
lot of hope. Are these the same VSELs which survived
Fig. 2 Immuno-localization of nuclear OCT-4 and cell surface SSEA-4 with propidium iodide as counterstain. Lower panel shows a single VSEL
stained for LINEAGE and CD45 markers (both negative) but is positive for CD133 and DAPI
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oncotherapy during childhood and also whether their
functionality is affected by oncotherapy - are difficult
questions to answer. VSELs are known to be easily
mobilized under stress conditions [24] and they survive
because of their quiescent nature. Thus we do not think
their functionality will be in anyways compromised due to
oncotherapy and will be mobilized from bone marrow if
body requires. Thus a pilot study wherein autologus bone
marrow/adipose tissue derived mesenchymal cells ex-
panded in a GMP facility are transplanted in azoospermic
testis needs to be urgently undertaken with a hope to
restore gonadal function from these stem cells.
Given the magnitude of the infertility concern in our
young adult survivors of childhood cancer (especially in
males), and the limited treatment options in the absence
of prior semen cryopreservation in any of the patients,
the results of this study have a huge and positive impli-
cation. A significant question is whether the surviving
VSELs observed in the testicular biopsies of cancer sur-
vivors will be able to restore spermatogenesis when the
niche cells are transplanted. It was recently reported
that inter-tubular random injections of syngenic Sertoli
cells or bone marrow derived mesenchymal cells into
the chemoablated testes of mice, were able to restore
spermatogenesis from persisting VSELs in mice, and that
the sperm developed post transplantation were found to
be capable of fertilizing mouse eggs [21]. Also, when
cells from chemoablated tubules were cultured, the in-
hibitory factors in vivo were overcome, Sertoli cells pro-
vided the niche and the surviving VSELs spontaneously
differentiated into sperm [28]. Similar VSELs also exist
in adult ovary surface epithelium [15, 17] and survive
chemotherapy [22]. Culture of intact ovary or surface
epithelial cells isolated from ovary of chemoablated mice
showed spontaneous differentiation into oocyte-like
structures since the inhibitory factors were overcome in
vitro [22]. These studies in mice highlight the potential
of VSELs and also the importance of niche to support
their function.
The recent editorial in Nature Medicine concludes that
for achieving regeneration from the stem cells – niche
cannot be ignored [33, 34]. Providing a healthy niche to
the testis of these azoospermic men could possibly lead to
resumption of spermatogenesis from surviving VSELs.
The results in mice are yet to be replicated in humans.
Azoospermic adult cancer survivors are potential benefi-
ciaries. Autologus mesenchymal cells from bone marrow/
adipose tissue may be expanded in culture and trans-
planted through inter-tubular route as a simple outpatient
procedure. They may act as a source of growth factors
Fig. 3 Relative mRNA expression of pluripotent markers (Oct-4A/Oct-4B, Nanog, Sox-2) and germ cell specific marker (Boule) by qRT-PCR in azoospermic
testes compared to normal testicular sample. Note that the pluripotent markers persist (unaltered or slightly increased) whereas the germ cell marker was
markedly reduced in azoospermic testicular sample. Pluripotent transcripts expression for various patients (P1, P2 and P3) is represented separately as
relative expression normalized to 18S RNA. Error bars represent standard deviation between two technical replicates for the same patient sample
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and cytokines required for VSELs differentiation into
sperm. It is essential to note that the transplanted mesen-
chymal cells do not differentiate into sperm (although
available literature may be confusing) – rather mesenchy-
mal cells facilitate differentiation of endogenous VSELs
into sperm. Thus the VSELs that survive oncotherapy in
cancer survivors may be targeted to restore fertility in can-
cer survivors. VSELs and their potential to restore gonadal
function will result in a huge paradigm shift in the field of
oncofertility, but the results of this study need to be vali-
dated by other groups and further studies in humans need
to be urgently undertaken. A similar clinical trial has
already been registered in the cancer trial registry of US
FDA [35]. In children undergoing cancer treatment
currently, cryopreservation of testicular tissue could serve
as a source of both germ cells and autologous Sertoli cells
which are the natural niche for testicular germ cells. The
approach of targeting endogenous VSELs to restore tes-
ticular function by providing a healthy niche could obviate
the need for expensive ART in the future.
Conclusions
Premature gonadal failure and subsequent infertility are
important and permanent late effects in adult survivors
of childhood cancers. The demonstration of testicular
VSELs which persist post cancer treatment and regain
their functionality in the presence of a healthy niche in
mice is a very encouraging observation. These results
are yet to be translated into clinical use Clinical trials
based on similar hypothesis are currently underway. We
hope that the results of the present study may help gain
insight into the underlying mechanisms that lead to in-
fertility in cancer survivors and also help restore fertility
in azoospermic adult survivors of childhood cancer who
were denied the opportunity to cryopreserve gonadal
tissue prior to therapy. Also this approach to restore fer-
tility may be of use to patients in our setting in whom
ART is not a viable option due to financial constraints.
In azoospermic adult cancer survivors desirous of start-
ing a family, autologus mesenchymal cells from bone
marrow/adipose tissue could be transplanted in the testis
with the hope of spermatogenesis restoration.
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